Unknown NA INTERVENTIONAL 1-arm NCT02185261

Interferon α for the Therapy of Minimal Residual Disease

Interferon α for the Therapy of Minimal Residual Disease Following Hematopoietic Stem Cell Transplantation

Sponsor: Peking University People's Hospital

Conditions Leukemia

Updated 7 times since 2017 Last updated: Jun 6, 2018 Started: Jun 30, 2014 Primary completion: Jun 30, 2021 Completion: Jun 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Leukemia, this trial is ongoing. The trial is conducted by Peking University People's Hospital and has accumulated 7 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting NA
Jul 2018 — Jan 2021 [monthly]

Recruiting NA

▶ Show 2 earlier versions

Jun 2018 — Jul 2018 [monthly]

Recruiting NA
Jan 2017 — Jun 2018 [monthly]

Recruiting NA

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University People's Hospital

Data source: Peking University People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China